Abstracts

Health

Search abstracts:

Replication-selective virotherapy for cancer: biological principles, risk management and future directions

Article Abstract:

Viral vectors and whole viruses offer some possibility of being used in conjunction with current treatments for cancer. Viral therapies require unique safety and regulatory issues yet include advantages such as no cross-resistance and the ability to destroy tumors with numerous mechanisms.

Research, Medical virology

---

Biological drug duo delivers one-two tumor punch

Article Abstract:

Interleukin (IL)-2 has become the only established immunotherapy approved by the US food and Drug Administration for the treatment of refractory melanoma and renal cancer. The results IL-2 are obtained and the causes associated with it are examined.

Government regulation, Licensing, certification and accreditation, Melanoma, Interleukin-2, Immunotherapy

---

Smallpox, polio and now a cancer vaccine?

Article Abstract:

Dendritic cells have been used as a vaccine for matastatic renal cancer. These and renal carcinoma cells may be applicable to other types of cancer.

Usage, Antigen presenting cells

Similar abstracts:

• Abstracts: Postoperative tailored radiotherapy for locally advanced breast carcinoma during pregnancy: a therapeutic dilemma
• Abstracts: Systemic adjuvant therapy for node-negative breast cancer: proven or premature? Update in oncology
• Abstracts: Adjuvant therapy for breast cancer: An additional hope. Breast cancer: early detection and prompt treatment are critical
• Abstracts: Intermittent claudication - be conservative. Intermittent claudication. Medical treatment of peripheral arterial disease and claudication
• Abstracts: Efficacy of automatic continuous positive airway pressure therapy that uses an estimated required pressure in the treatment of the obstructive sleep apnea syndrome

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.